Why Insulet Corporation (NASDAQ:PODD) Looks Like A Quality Company

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Equity (ROE). By way of learni

Simply Wall StJul 2 03:09

Insulet Tops S&P 500 Growth Chart for Q2 as It Gains Market Share in the Diabetes Space

Seeking AlphaJun 29 23:35

Wells Fargo Maintains Insulet(PODD.US) With Buy Rating, Maintains Target Price $240

Wells Fargo analyst Larry Biegelsen maintains $Insulet(PODD.US)$ with a buy rating, and maintains the target price at $240.According to TipRanks data, the analyst has a success rate of 58.6% and a tot

Futu NewsJun 28 21:31 · Ratings

Form 144 | Insulet(PODD.US) Insider Proposes to Sell 4.07 Million in Common Stocks

SEC FILLINGS DISCLOSED/ Jun 25, $Insulet(PODD.US)$ Insider Petrovic Shacey intends to sell 20,000 shares of its common stock on Jun 25, with a total market value of approximately $4.07 million. Sou

Futu NewsJun 26 04:23

Insulet Points Its Insulin Pump at the Big Diabetes Market: Type 2 -- Barrons.com

An automated insulin pump markedly improved the health of patients with Type 2 diabetes, the pump maker Insulet told a conference last weekend. The company is asking regulators to clear its Omnipod pump as the first automated dispenser for the 30 million Americans with the disorder.

Barron'sJun 26 00:07

Is weight loss medicine or stock market bomb? Eli Lilly and Co's new drug tirzepatide caused a sharp drop in sleep device stocks.

The recent clinical trial results of the new weight loss drug tirzepatide have not only caused a sensation in the medical community, but also stirred up waves in the stock market.

Zhitong FinanceJun 25 07:50